Marcum Microcap Conference June 2, 2016 New York, NY LISHAN

Marcum Microcap Conference June 2, 2016 New York, NY LISHAN

AKLOG, MD Chairman & CEO Nasdaq:PAVMU 1

presentation contains certain forward-looking statements that involve risks and uncertainties. Actual results and events may differ

significantly from results and events discussed in forward-looking statements. Factors that might cause or contribute to such

differences include, but are not limited to, those discussed in "Risk Factors" in our Annual Report on Form 10-K and

subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. We undertake no obligation to update

publicly any forward-looking statements to reflect new information, events, or circumstances after the date they were made. This

presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any

sale of securities in any jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification

under the securities laws of any such jurisdiction. PAVmed has not yet sought nor received clearance from the FDA or any other

regulatory agency for any of the products described in this presentation. ir.pavm.com info@pavm.com Nasdaq:PAVMU 2

Innovative multi-product

medical device company Leadership team of entrepreneurs with a strong track record of value creation Unique, proven business model

focused on capital efficiency and speed to market Deep, expanding pipeline of innovative products across a broad spectrum of clinical

conditions addressing >$4B market opportunities Nasdaq:PAVMU 3

with strong record of value creation LISHAN AKLOG, MD CHAIRMAN & CEO A.B. Physics, magna cum laude Phi Beta Kappa M.D., cum

laude General Surgery Resident Cardiothoracic Surgery Resident Assistant Professor Associate Surgeon Associate Chief of Cardiac

Surgery Assistant Professor Director of Minimally Invasive Cardiac Surgery Chair of the Cardiovascular Center Chief of Cardiovascular

Surgery Associate Professor of Surgery Founding Partner Chairman and CTO, Vortex Medical Senior Advisor, Director, Saphena Medical,

Kaleidoscope Medical and Cruzar Medical BRIAN DEGUZMAN, MD CHIEF MEDICAL OFFICER B.S. Biology M.D. General Surgery Resident Cardiac

Surgery Research Fellow Cardiothoracic Surgery Resident Clinical Associate Associate Surgeon Assistant Professor of Surgery Associate

Chief of Cardiovascular Surgery Assistant Professor of Surgery Founding Partner CMO, Vortex Medical CEO, Kaleidoscope Medical

Senior Advisor, Director Saphena Medical and Cruzar Medical MICHAEL GLENNON VICE CHAIRMAN B.A., Business Administration Endoscopy

and Surgical Instrument Territory Sales Manager Cardiac Surgery Territory and Regional Sales Manager CRM Sales Manager CRM District

Sales Manager Senior Vice President, Sales and Marketing Founding Partner CEO, Vortex Medical, Saphena Medical and Cruzar Medical

Senior Advisor, Director Kaleidoscope Medical Nasdaq:PAVMU 4

prior track record of success ANGIOVAC Endovascular device to move large lots and other material VENOPAX Endoscopic

vessel harvest device for coronary bypass surgery HOUDINI Device to treat chronic total occlusion of peripheral arteries

KALEIDOSCOPE Reversible inferior vena cava filter Acquired for $55 Million by Angiodynamics (Nasdaq:ANGO) 3rd Gen device now marketed

across the US Evaluating acquisition overtures from 4 companies FDA 510(k) clearance December 2015 Commercial Launch in progress

with Key Opinion Leaders Submitted to FDA for 510(k) clearance Evaluating acquisition overtures by large strategics Nasdaq:PAVMU

track record of success Nasdaq:PAVMU 6

capital efficiency and speed to market TIME AND CAPITAL TO FDA CLEARANCE PAVmed Model 23 Months Typical Company 61 Months 0 12

24 36 48 60 Months PAVmed Model $3M Typical Company $31M $0 $10,000,000 $20,000,000 $30,000,000 Dollars * Typical Company data

from Markower, et al. FDA Impact on US Medical Technology Innovation 2010 Nasdaq:PAVMU 7

criteria drive commercial opportunity Reimbursement Profile Technology Profile Unmet Clinical Need Regulatory Profile High Margin

Product Attractive Market Commercial Opportunity Nasdaq:PAVMU 8

Key business processes

drive capital efficiency and speed Outsourced Best-in-class Process Experts Parallel Development Processes Regulatory Strategy

Capital Efficiency Speed To Market Light Infrastructure Low Fixed Costs Flexible Commercialization Strategy Nasdaq:PAVMU 9

Lead products provide

near-term value creation opportunities PortIO Long-term Implantable Vascular Access Device CarpX Percutaneous Device to Treat

Carpal Tunnel Syndrome Caldus Disposable Tissue Ablation Devices NextCath Self-Anchoring Short-Term Catheters NextFlo Highly Accurate

Disposable Infusion Pump *PAVmed has not yet sought nor received clearance from the FDA or any other regulatory agency for any

of these products. Nasdaq:PAVMU 10

Lead products provide

near-term value creation opportunities PRODUCT ADDRESSABLE MARKET REGULATORY PATH COMMERCIALIZATION INITIAL CHANNEL TARGET DATE

PortIO Long-term Implantable Vascular Access Devices $500M/$50M 510(k) Independent Distributors Q2 2017 Caldus Disposable Tissue

Ablation Devices $200M/$100M 510(k) Independent Distributors Q3 2017 Disposable Renal Denervation Devices $5B/$1B CE Mark / Emerging

Markets Independent Distributors Q2 2018 CarpX Percutaneous Treatment of Carpal Tunnel Syndrome $1.5B/$750M 510(k) Independent

Distributors Q3 2017 NextCath Self-Anchoring Short-Term Catheters $2B/$1B 510(k) Corporate Distribution Agreement Q2 2017 NextFlo

Highly Accurate Disposable Infusion Pump $500M 510(k) Corporate Distribution Agreement Q2 2017 *PAVmed has not yet sought nor

received clearance from the FDA or any other regulatory agency for any of these products. Nasdaq:PAVMU 11

Long-term implantable

vascular access ports Commonly known as "Port-a-Caths" Most common indications Chemotherapy Intravenous nutrition

Other long-term medication regimens Hemophilia treatments Antibiotics New biologics Market ~400,000 US patients/year in 2012*

Estimated $400-500 million market CAGR 5-8% Nasdaq:PAVMU 12

current device limitations OCCLUSIONS ~30% of patients Potentially more serious complications (DVT, PE) Requires clot-busting

medications or a repeat procedure Significant economic burden POOR VEINS >10% of patients Kidney failure patients on dialysis

Prior chemotherapy or other need for access Patients with pacemaker and defibrillators leads OTHER Regular flushes Surgical insertion

and removal Bloodstream infections Limitations are driven by INTRAVASCULAR COMPONENT Nasdaq:PAVMU 13

PAVmed Solution PortIOTM Implantable INTRAOSSEOUS Vascular Access Port NO INTRAVASCULAR COMPONENT INTRAOSSEOUS INFUSION Intraosseous

= into the bone marrow Well established access site for ACUTE Infusions Pediatric ER/Military Trauma Good bioequivalence to IV

Infusions Has not previously been commercially used for LONG-TERM Infusions Nasdaq:PAVMU 14

PAVmed Solution Fewer Complications Fewer occlusions Potential for fewer, less serious infections More Cost Effective Fewer occlusions

No need for regular flushes No radiographic confirmation Shift procedures less expensive locale Less Invasive Near percutaneous

insertion/removal More Versatile Near limitless number of potential access sites Target commercialization Q2-2017 Initial

target poor venous access patients Nasdaq:PAVMU 15

Carpal Tunnel Syndrome

Estimated prevalence 3-8% of adults = ~5M >3M office visits per year Most common cumulative trauma disorder Most common occupational

injury Most common cause of lost work days Billions of dollars in workman s comp Carpal Tunnel Surgery Over 600,000 US procedures

per year Traditional vs. Endoscopic Nasdaq:PAVMU 16

current device limitations TRADITIONAL SURGERY IS INVASIVE 2 inch incision Surgical procedure Post-operative Pain 3-4

month recovery ENDOSCOPIC SURGERY IS LESS EFFECTIVE Higher recurrence Higher reoperation rate Increased nerve injury Nasdaq:PAVMU

PAVmed Solution PERCUTANEOUS device to treat Carpal Tunnel Syndrome NO SURGICAL INCISION CARPX Balloon catheter with bipolar cutting

electrode Inserted into tunnel over a guidewire under ultrasound guidance Cleanly cuts ligament from inside out in <1.5 sec

No visible injury to surrounding structures Nasdaq:PAVMU 18

PAVmed Solution Less Invasive Truly percutaneous No surgical incision or dissection More Cost Effective Shift procedures interventional

lab or office Shorten procedural times Fewer Complications Better nerve protection Greater lateral dissection may decrease recurrence

rates Expanded Market Lower threshold for intervention Target commercialization Q3-2017 Nasdaq:PAVMU 19

opportunities for value creation Caldus RND CE Clearance CarpX Commercialization Caldus General Commercialization NextCath, NextFlo

Commercialization PortIO Commercialization Caldus General FDA Submission CarpX FDA Submission NextCath, NextFlo FDA Submission

PortIO FDA Submission 2018 2017 2016 Nasdaq:PAVMU 20

Corporate Highlights

Founded June 2014 Nasdaq IPO Completed April 28, 2016 1,060,000 Units (1 share, 1 warrant) Sold at $5.00 per Unit $5,300,000 gross

proceeds Capital Structure Total Shares Outstanding 13,310,000 Total Warrants Outstanding 10,522,741 Units split into Shares/Warrants

July 28, 2016 Market Performance IPO Price $5.00 High Close $15.93 Low Close $8.06 Last Close $11.10 Market Cap $149M Post-IPO

Performance 1 day +61% 30-day +122% Nasdaq:PAVMU 21